Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study
- PMID: 25855392
- DOI: 10.1007/s00392-015-0826-3
Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study
Abstract
Objectives: T1 mapping by cardiac magnetic resonance imaging (CMR) is able to determine the extracellular volume fraction. Wild-type transthyretin amyloidosis (WT-ATTR) is characterized by extracellular amyloid deposition in the heart. Recent reports indicated a reduction of left ventricular (LV) myocardial mass in WT-ATTR after consumption of epigallocatechin-3-gallate, the main catechin in green tea. It remained unclear, whether reduction of LV myocardial mass reflects decrease of amyloid load or progressive atrophy of cardiomyocytes.
Methods: This study included 7 male patients with CMR repetitively performed before and 12 months after daily consumption of green tea extract (600 mg epigallocatechin-3-gallate). Short axis slices as well as 2-, 3-, and 4-chamber views were acquired using SSFP sequences. T1 mapping was created out of 11 mid-ventricular short axis views with increasing inversion times using a single breath-hold modified look-locker inversion recovery sequence before and 15 min after Gadolinium contrast administration.
Results: After 12 months, a significant decrease of LV myocardial mass [198 (160; 212) vs. 180 (142; 204) g; p < 0.05] was observed. Moreover, a significant decrease of native [T1 1110 (1072; 1150) ms vs. 1080 (970; 1101), p < 0.05 or p = 0.03] was noticed. The calculated extracellular volume decreased in 5 patients (62.5%) by 7% and increased in 2 patients (37.5%) by 9.5%, in trend resulting in a (not significant) decrease of median ECV by 2.4%. Left ventricular ejection fraction (LVEF) [57 (48; 65) vs. 55 (47; 64) %; p = 0.3] remained unchanged.
Conclusions: This study provided further evidence of LV myocardial mass reduction in patients with WT-ATTR daily consuming green tea extract. Additionally, this study gave first insights into the histomorphological correlate of LV mass reduction using T1 mapping. LV mass reduction appeared to be rather due to a decrease of amyloid load than atrophy of cardiomyocytes.
Similar articles
-
Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study.Drug Des Devel Ther. 2015 Dec 4;9:6319-25. doi: 10.2147/DDDT.S96893. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26673202 Free PMC article.
-
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging.J Intern Med. 2015 May;277(5):605-14. doi: 10.1111/joim.12324. Epub 2014 Nov 24. J Intern Med. 2015. PMID: 25346163
-
Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.Int J Cardiol. 2024 May 15;403:131892. doi: 10.1016/j.ijcard.2024.131892. Epub 2024 Feb 19. Int J Cardiol. 2024. PMID: 38382853
-
Extracellular Volume Associates With Outcomes More Strongly Than Native or Post-Contrast Myocardial T1.JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 1):44-54. doi: 10.1016/j.jcmg.2019.03.017. Epub 2019 May 15. JACC Cardiovasc Imaging. 2020. PMID: 31103587
-
Diagnostic and Prognostic Value of Non-late Gadolinium Enhancement Cardiac Magnetic Resonance Parameters in Cardiac Amyloidosis.Curr Probl Cardiol. 2023 Apr;48(4):101573. doi: 10.1016/j.cpcardiol.2022.101573. Epub 2022 Dec 28. Curr Probl Cardiol. 2023. PMID: 36586704 Review.
Cited by
-
Novel pharmacotherapies for cardiac amyloidosis.Pharmacol Ther. 2017 Dec;180:129-138. doi: 10.1016/j.pharmthera.2017.06.011. Epub 2017 Jun 22. Pharmacol Ther. 2017. PMID: 28648829 Free PMC article. Review.
-
Narrative review of pharmacotherapy for transthyretin cardiac amyloid.Ann Transl Med. 2021 Mar;9(6):519. doi: 10.21037/atm-20-4636. Ann Transl Med. 2021. PMID: 33850916 Free PMC article. Review.
-
Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects.Brain Sci. 2020 Dec 9;10(12):952. doi: 10.3390/brainsci10120952. Brain Sci. 2020. PMID: 33316911 Free PMC article.
-
Hereditary transthyretin amyloidosis overview.Neurol Sci. 2022 Dec;43(Suppl 2):595-604. doi: 10.1007/s10072-020-04889-2. Epub 2020 Nov 14. Neurol Sci. 2022. PMID: 33188616 Free PMC article. Review.
-
Amyloid and the Heart.Curr Cardiol Rep. 2019 Dec 3;21(12):164. doi: 10.1007/s11886-019-1230-9. Curr Cardiol Rep. 2019. PMID: 31792619 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials